Nicholas B. Norgard

585 total citations
31 papers, 413 citations indexed

About

Nicholas B. Norgard is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Pharmacology. According to data from OpenAlex, Nicholas B. Norgard has authored 31 papers receiving a total of 413 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Cardiology and Cardiovascular Medicine, 8 papers in Surgery and 5 papers in Pharmacology. Recurrent topics in Nicholas B. Norgard's work include Antiplatelet Therapy and Cardiovascular Diseases (12 papers), Acute Myocardial Infarction Research (5 papers) and Atrial Fibrillation Management and Outcomes (4 papers). Nicholas B. Norgard is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (12 papers), Acute Myocardial Infarction Research (5 papers) and Atrial Fibrillation Management and Outcomes (4 papers). Nicholas B. Norgard collaborates with scholars based in United States, United Kingdom and Italy. Nicholas B. Norgard's co-authors include Geoffrey C. Wall, Mazen Abu‐Fadel, James J. DiNicolantonio, George L. Dale, Angel López‐Candales, Sandra L. Kane‐Gill, Eliot Schechter, David L. DeRemer, Paul M. Stranges and Robert B. Parker and has published in prestigious journals such as Circulation, Antimicrobial Agents and Chemotherapy and Thrombosis and Haemostasis.

In The Last Decade

Nicholas B. Norgard

30 papers receiving 401 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nicholas B. Norgard United States 14 213 92 59 49 43 31 413
Mona Razavian Australia 6 176 0.8× 90 1.0× 23 0.4× 37 0.8× 17 0.4× 7 470
Dongmei Wang China 13 281 1.3× 133 1.4× 26 0.4× 40 0.8× 29 0.7× 49 512
W. Dieter Paar Germany 12 333 1.6× 103 1.1× 42 0.7× 55 1.1× 34 0.8× 34 539
Çağdaş Akgüllü Türkiye 14 123 0.6× 65 0.7× 23 0.4× 38 0.8× 21 0.5× 42 358
Aileen B Luzier United States 11 239 1.1× 69 0.8× 34 0.6× 27 0.6× 35 0.8× 17 482
Hacene Nedjar Canada 13 148 0.7× 108 1.2× 161 2.7× 39 0.8× 30 0.7× 21 487
Enrico Geraci Italy 9 305 1.4× 123 1.3× 40 0.7× 19 0.4× 67 1.6× 12 495
Elizabeth Lee Lewandrowski United States 13 330 1.5× 83 0.9× 16 0.3× 20 0.4× 36 0.8× 28 557
Jean-Pierre Boissel France 7 521 2.4× 109 1.2× 20 0.3× 42 0.9× 18 0.4× 12 633
Zachary A. Stacy United States 11 168 0.8× 67 0.7× 28 0.5× 125 2.6× 38 0.9× 25 300

Countries citing papers authored by Nicholas B. Norgard

Since Specialization
Citations

This map shows the geographic impact of Nicholas B. Norgard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas B. Norgard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas B. Norgard more than expected).

Fields of papers citing papers by Nicholas B. Norgard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas B. Norgard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas B. Norgard. The network helps show where Nicholas B. Norgard may publish in the future.

Co-authorship network of co-authors of Nicholas B. Norgard

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas B. Norgard. A scholar is included among the top collaborators of Nicholas B. Norgard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas B. Norgard. Nicholas B. Norgard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
López‐Candales, Angel, et al.. (2023). Heart Failure with Preserved Left Ventricular Ejection Fraction: A Complex Conundrum Simply Not Limited to Diastolic Dysfunction. Cardiovascular Therapeutics. 2023. 1–18. 3 indexed citations
3.
Norgard, Nicholas B., et al.. (2023). Growth Differentiation Factor 15 (GDF-15), a New Biomarker in Heart Failure Management. Current Heart Failure Reports. 20(4). 287–299. 17 indexed citations
4.
Bhat, Abid, et al.. (2022). Obstructive Sleep Apnea and Cardiovascular Diseases: Sad Realities and Untold Truths regarding Care of Patients in 2022. Cardiovascular Therapeutics. 2022. 1–10. 19 indexed citations
5.
Norgard, Nicholas B., et al.. (2017). Towards Precision in HF Pharmacotherapy. Current Heart Failure Reports. 14(1). 1–6. 3 indexed citations
6.
Norgard, Nicholas B.. (2017). Obesity and Altered Aspirin Pharmacology. Clinical Pharmacokinetics. 57(6). 663–672. 31 indexed citations
7.
Norgard, Nicholas B., et al.. (2016). Oral Administration of Sustained Release Niacin Inhibits Platelet Aggregation. Current Clinical Pharmacology. 11(1). 43–46. 2 indexed citations
8.
Deal, Eli N., Paul M. Stranges, Whitney D. Maxwell, et al.. (2016). The Importance of Research and Scholarly Activity in Pharmacy Training. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 36(12). e200–e205. 49 indexed citations
9.
Norgard, Nicholas B. & James J. DiNicolantonio. (2013). Clopidogrel, Prasugrel, or Ticagrelor? A Practical Guide to Use of Antiplatelet Agents in Patients With Acute Coronary Syndromes. Postgraduate Medicine. 125(4). 91–102. 14 indexed citations
10.
Norgard, Nicholas B., et al.. (2012). Novel anticoagulants in atrial fibrillation stroke prevention. Therapeutic Advances in Chronic Disease. 3(3). 123–136. 14 indexed citations
11.
Norgard, Nicholas B., et al.. (2012). Dofetilide Overdose—A Case of Unintentional Ingestion Due to Misinterpretation of the Dose. Journal of Pharmacy Technology. 28(6). 258–263. 3 indexed citations
12.
Norgard, Nicholas B., et al.. (2010). Profound thrombocytopenia after primary exposure to eptifibatide. Drug Healthcare and Patient Safety. 2. 163–163. 1 indexed citations
13.
Malinin, Alex I., Dániel Aradi, Wiktor Kuliczkowski, et al.. (2010). The in vitro effects of niacin on platelet biomarkers in human volunteers. Thrombosis and Haemostasis. 104(8). 311–317. 17 indexed citations
14.
Norgard, Nicholas B.. (2009). Cangrelor: a novel P2Y12receptor antagonist. Expert Opinion on Investigational Drugs. 18(8). 1219–1230. 15 indexed citations
15.
Norgard, Nicholas B. & Mazen Abu‐Fadel. (2009). Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Vascular Health and Risk Management. 5. 873–873. 27 indexed citations
16.
Norgard, Nicholas B., et al.. (2008). Pharmacotherapy for Heart Failure with Left Ventricular Dysfunction: Beyond Angiotensin‐Converting Enzyme Inhibitors and β‐Blockers. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 28(7). 920–931. 1 indexed citations
17.
Norgard, Nicholas B., et al.. (2008). Clopidogrel Attenuates Coated-platelet Production in Patients Undergoing Elective Coronary Catheterization. Journal of Cardiovascular Pharmacology. 52(6). 536–539. 29 indexed citations
18.
Norgard, Nicholas B., et al.. (2006). Olanzapine‐Associated Neuroleptic Malignant Syndrome. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 26(8). 1180–1182. 14 indexed citations
19.
Norgard, Nicholas B. & Geoffrey C. Wall. (2005). Possible drug rash with eosinophilia and systemic symptoms syndrome after exposure to epoetin alfa. American Journal of Health-System Pharmacy. 62(23). 2524–2526. 4 indexed citations
20.
Mellemgaard, Anders, et al.. (1990). [Renal cancer in Denmark in 1943-1986. Cancer statistics number 27].. PubMed. 152(44). 3255–8. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mona Razavian Breakdown of academic impact, for papers by Dongmei Wang Breakdown of academic impact, for papers by W. Dieter Paar Breakdown of academic impact, for papers by Çağdaş Akgüllü Breakdown of academic impact, for papers by Aileen B Luzier Breakdown of academic impact, for papers by Hacene Nedjar Breakdown of academic impact, for papers by Enrico Geraci Breakdown of academic impact, for papers by Elizabeth Lee Lewandrowski Breakdown of academic impact, for papers by Jean-Pierre Boissel Breakdown of academic impact, for papers by Zachary A. Stacy
Rankless by CCL
2026